Alnylam Pharmaceuticals (ALNY) is a publicly traded Healthcare sector company. As of July 5, 2026, ALNY trades at $312.78 with a market cap of $41.76B and a P/E ratio of 130.87. ALNY moved +3.72% today. Year to date, ALNY is -21.26%; over the trailing twelve months it is -5.15%. Its 52-week range spans $205.87 to $495.55. Analyst consensus is strong buy with an average price target of $456.07. Rallies surfaces ALNY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for ALNY shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $312.78 |
| Market Cap | $41.76B |
| P/E Ratio | 130.87 |
| EPS | $2.39 |
| Dividend Yield | 0.00% |
| 52-Week High | $495.55 |
| 52-Week Low | $205.87 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.71B |
| Net Income | $313.75M |
| Gross Margin | 81.77% |
19 analysts cover ALNY: 0 strong buy, 17 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $456.07.